GEVA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Synageva BioPharma Corp's annual construction in progress increased from Dec. 2012 ($0.00 Mil) to Dec. 2013 ($1.71 Mil) but then declined from Dec. 2013 ($1.71 Mil) to Dec. 2014 ($0.00 Mil).
It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.
Synageva BioPharma Corp Annual Data
Synageva BioPharma Corp Quarterly Data